JP2008500373A - ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 - Google Patents
ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 Download PDFInfo
- Publication number
- JP2008500373A JP2008500373A JP2007515450A JP2007515450A JP2008500373A JP 2008500373 A JP2008500373 A JP 2008500373A JP 2007515450 A JP2007515450 A JP 2007515450A JP 2007515450 A JP2007515450 A JP 2007515450A JP 2008500373 A JP2008500373 A JP 2008500373A
- Authority
- JP
- Japan
- Prior art keywords
- myostatin
- disease
- protein
- preparation
- kerberos
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000202252 Cerberus Species 0.000 title claims abstract description 38
- 102100039939 Growth/differentiation factor 8 Human genes 0.000 claims abstract description 161
- 108010056852 Myostatin Proteins 0.000 claims abstract description 156
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 62
- 229920001184 polypeptide Polymers 0.000 claims abstract description 54
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 54
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 49
- 201000010099 disease Diseases 0.000 claims abstract description 40
- 102100040898 Growth/differentiation factor 11 Human genes 0.000 claims abstract description 29
- 101710194452 Growth/differentiation factor 11 Proteins 0.000 claims abstract description 28
- 101001032872 Homo sapiens Gremlin-1 Proteins 0.000 claims abstract description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 102
- 102000004169 proteins and genes Human genes 0.000 claims description 96
- 230000027455 binding Effects 0.000 claims description 76
- 238000000034 method Methods 0.000 claims description 66
- 101000912351 Homo sapiens DAN domain family member 5 Proteins 0.000 claims description 57
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 45
- 102100026233 DAN domain family member 5 Human genes 0.000 claims description 42
- 101710010675 Cerberus Proteins 0.000 claims description 39
- 102100025745 Cerberus Human genes 0.000 claims description 39
- 210000003205 muscle Anatomy 0.000 claims description 38
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 37
- 239000005557 antagonist Substances 0.000 claims description 34
- 102100024505 Bone morphogenetic protein 4 Human genes 0.000 claims description 32
- 239000003112 inhibitor Substances 0.000 claims description 29
- 210000004027 cell Anatomy 0.000 claims description 28
- 150000001875 compounds Chemical class 0.000 claims description 27
- 239000003814 drug Substances 0.000 claims description 26
- 230000011664 signaling Effects 0.000 claims description 26
- 108010049955 Bone Morphogenetic Protein 4 Proteins 0.000 claims description 25
- 238000002360 preparation method Methods 0.000 claims description 25
- 150000001413 amino acids Chemical class 0.000 claims description 24
- 238000011161 development Methods 0.000 claims description 22
- 230000018109 developmental process Effects 0.000 claims description 21
- 201000006935 Becker muscular dystrophy Diseases 0.000 claims description 20
- 201000006938 muscular dystrophy Diseases 0.000 claims description 19
- 208000002320 spinal muscular atrophy Diseases 0.000 claims description 19
- 210000001519 tissue Anatomy 0.000 claims description 19
- 238000001727 in vivo Methods 0.000 claims description 17
- 208000011580 syndromic disease Diseases 0.000 claims description 17
- 230000004927 fusion Effects 0.000 claims description 16
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 15
- 206010006895 Cachexia Diseases 0.000 claims description 14
- 241001465754 Metazoa Species 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 101000799193 Homo sapiens Activin receptor type-1C Proteins 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 101000799189 Homo sapiens Activin receptor type-1B Proteins 0.000 claims description 11
- 239000000427 antigen Substances 0.000 claims description 11
- 108091007433 antigens Proteins 0.000 claims description 11
- 102000036639 antigens Human genes 0.000 claims description 11
- 102000037865 fusion proteins Human genes 0.000 claims description 11
- 108020001507 fusion proteins Proteins 0.000 claims description 11
- 230000014509 gene expression Effects 0.000 claims description 11
- 102000052506 human DAND5 Human genes 0.000 claims description 11
- 230000001965 increasing effect Effects 0.000 claims description 11
- 102100034135 Activin receptor type-1C Human genes 0.000 claims description 10
- 108010023082 activin A Proteins 0.000 claims description 10
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 101000914195 Homo sapiens Cerberus Proteins 0.000 claims description 9
- 230000002159 abnormal effect Effects 0.000 claims description 9
- 210000000577 adipose tissue Anatomy 0.000 claims description 9
- 208000022531 anorexia Diseases 0.000 claims description 9
- 206010061428 decreased appetite Diseases 0.000 claims description 9
- 229940079593 drug Drugs 0.000 claims description 9
- 230000012010 growth Effects 0.000 claims description 9
- 230000002503 metabolic effect Effects 0.000 claims description 9
- 230000037257 muscle growth Effects 0.000 claims description 9
- 238000003571 reporter gene assay Methods 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 8
- 208000005264 motor neuron disease Diseases 0.000 claims description 8
- 201000000585 muscular atrophy Diseases 0.000 claims description 8
- 230000002093 peripheral effect Effects 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 7
- 208000025966 Neurological disease Diseases 0.000 claims description 7
- 230000007812 deficiency Effects 0.000 claims description 7
- 208000030159 metabolic disease Diseases 0.000 claims description 7
- 208000013315 neuromuscular junction disease Diseases 0.000 claims description 7
- 230000001575 pathological effect Effects 0.000 claims description 7
- 208000037415 AIDS wasting syndrome Diseases 0.000 claims description 6
- 208000003577 HIV wasting syndrome Diseases 0.000 claims description 6
- 101000617738 Homo sapiens Survival motor neuron protein Proteins 0.000 claims description 6
- 108060003951 Immunoglobulin Proteins 0.000 claims description 6
- 102100022745 Laminin subunit alpha-2 Human genes 0.000 claims description 6
- 201000009342 Limb-girdle muscular dystrophy Diseases 0.000 claims description 6
- 208000026072 Motor neurone disease Diseases 0.000 claims description 6
- 208000029578 Muscle disease Diseases 0.000 claims description 6
- 208000021642 Muscular disease Diseases 0.000 claims description 6
- 201000002481 Myositis Diseases 0.000 claims description 6
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 6
- 102100021947 Survival motor neuron protein Human genes 0.000 claims description 6
- 201000006815 congenital muscular dystrophy Diseases 0.000 claims description 6
- 201000009338 distal myopathy Diseases 0.000 claims description 6
- 102000018358 immunoglobulin Human genes 0.000 claims description 6
- 208000010693 Charcot-Marie-Tooth Disease Diseases 0.000 claims description 5
- 208000004117 Congenital Myasthenic Syndromes Diseases 0.000 claims description 5
- 125000000539 amino acid group Chemical group 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 5
- 238000009826 distribution Methods 0.000 claims description 5
- 208000018360 neuromuscular disease Diseases 0.000 claims description 5
- 230000011164 ossification Effects 0.000 claims description 5
- 239000013598 vector Substances 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- 206010058892 Carnitine deficiency Diseases 0.000 claims description 4
- 206010050215 Carnitine palmitoyltransferase deficiency Diseases 0.000 claims description 4
- 208000015374 Central core disease Diseases 0.000 claims description 4
- 206010010356 Congenital anomaly Diseases 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 206010053185 Glycogen storage disease type II Diseases 0.000 claims description 4
- 208000027747 Kennedy disease Diseases 0.000 claims description 4
- 108700006394 Lactate Dehydrogenase Deficiency Proteins 0.000 claims description 4
- 201000010743 Lambert-Eaton myasthenic syndrome Diseases 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 201000002169 Mitochondrial myopathy Diseases 0.000 claims description 4
- 201000009623 Myopathy Diseases 0.000 claims description 4
- 108700010203 Phosphoglycerate Kinase 1 Deficiency Proteins 0.000 claims description 4
- 208000033526 Proximal spinal muscular atrophy type 3 Diseases 0.000 claims description 4
- 230000005856 abnormality Effects 0.000 claims description 4
- 230000037182 bone density Effects 0.000 claims description 4
- 201000007303 central core myopathy Diseases 0.000 claims description 4
- CVSVTCORWBXHQV-UHFFFAOYSA-N creatine Chemical compound NC(=[NH2+])N(C)CC([O-])=O CVSVTCORWBXHQV-UHFFFAOYSA-N 0.000 claims description 4
- 201000004502 glycogen storage disease II Diseases 0.000 claims description 4
- 239000003102 growth factor Substances 0.000 claims description 4
- 208000023692 inborn mitochondrial myopathy Diseases 0.000 claims description 4
- 201000004815 juvenile spinal muscular atrophy Diseases 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 206010028417 myasthenia gravis Diseases 0.000 claims description 4
- 208000029308 periodic paralysis Diseases 0.000 claims description 4
- 238000000746 purification Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 208000016505 systemic primary carnitine deficiency disease Diseases 0.000 claims description 4
- 102100032123 AMP deaminase 1 Human genes 0.000 claims description 3
- 102100034134 Activin receptor type-1B Human genes 0.000 claims description 3
- 229940122361 Bisphosphonate Drugs 0.000 claims description 3
- 208000037149 Facioscapulohumeral dystrophy Diseases 0.000 claims description 3
- 208000008589 Obesity Diseases 0.000 claims description 3
- 150000004663 bisphosphonates Chemical class 0.000 claims description 3
- 230000009918 complex formation Effects 0.000 claims description 3
- 230000002124 endocrine Effects 0.000 claims description 3
- 230000001815 facial effect Effects 0.000 claims description 3
- 208000008570 facioscapulohumeral muscular dystrophy Diseases 0.000 claims description 3
- 201000008319 inclusion body myositis Diseases 0.000 claims description 3
- 230000001939 inductive effect Effects 0.000 claims description 3
- 230000004807 localization Effects 0.000 claims description 3
- 235000020824 obesity Nutrition 0.000 claims description 3
- 229920002704 polyhistidine Polymers 0.000 claims description 3
- 239000002510 pyrogen Substances 0.000 claims description 3
- 208000000943 scapulohumeral muscular dystrophy Diseases 0.000 claims description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 3
- FMKLAIBZMCURLI-BFVRRIQPSA-N 15-Keto-13,14-dihydroprostaglandin A2 Chemical compound CCCCCC(=O)CC[C@H]1C=CC(=O)[C@@H]1C\C=C/CCCC(O)=O FMKLAIBZMCURLI-BFVRRIQPSA-N 0.000 claims description 2
- 102100032922 ATP-dependent 6-phosphofructokinase, muscle type Human genes 0.000 claims description 2
- 108010029692 Bisphosphoglycerate mutase Proteins 0.000 claims description 2
- 208000006386 Bone Resorption Diseases 0.000 claims description 2
- 206010068597 Bulbospinal muscular atrophy congenital Diseases 0.000 claims description 2
- 206010007559 Cardiac failure congestive Diseases 0.000 claims description 2
- 108010076667 Caspases Proteins 0.000 claims description 2
- 102000011727 Caspases Human genes 0.000 claims description 2
- ACTIUHUUMQJHFO-UHFFFAOYSA-N Coenzym Q10 Natural products COC1=C(OC)C(=O)C(CC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UHFFFAOYSA-N 0.000 claims description 2
- 229940122459 Glutamate antagonist Drugs 0.000 claims description 2
- 102100029492 Glycogen phosphorylase, muscle form Human genes 0.000 claims description 2
- 206010019280 Heart failures Diseases 0.000 claims description 2
- 101000730838 Homo sapiens ATP-dependent 6-phosphofructokinase, muscle type Proteins 0.000 claims description 2
- 101000700475 Homo sapiens Glycogen phosphorylase, muscle form Proteins 0.000 claims description 2
- 101100351819 Homo sapiens PGAM2 gene Proteins 0.000 claims description 2
- 206010020850 Hyperthyroidism Diseases 0.000 claims description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims description 2
- 108010025020 Nerve Growth Factor Proteins 0.000 claims description 2
- 102000007072 Nerve Growth Factors Human genes 0.000 claims description 2
- 102100037385 Phosphoglycerate mutase 2 Human genes 0.000 claims description 2
- 102000009097 Phosphorylases Human genes 0.000 claims description 2
- 108010073135 Phosphorylases Proteins 0.000 claims description 2
- 229940123924 Protein kinase C inhibitor Drugs 0.000 claims description 2
- 208000032225 Proximal spinal muscular atrophy type 1 Diseases 0.000 claims description 2
- 208000033522 Proximal spinal muscular atrophy type 2 Diseases 0.000 claims description 2
- 208000003954 Spinal Muscular Atrophies of Childhood Diseases 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- 208000010399 Wasting Syndrome Diseases 0.000 claims description 2
- 208000026481 Werdnig-Hoffmann disease Diseases 0.000 claims description 2
- 208000006269 X-Linked Bulbo-Spinal Atrophy Diseases 0.000 claims description 2
- 230000009815 adipogenic differentiation Effects 0.000 claims description 2
- 201000006960 adult spinal muscular atrophy Diseases 0.000 claims description 2
- 230000032683 aging Effects 0.000 claims description 2
- 239000003194 amino acid receptor blocking agent Substances 0.000 claims description 2
- 230000024279 bone resorption Effects 0.000 claims description 2
- 230000015556 catabolic process Effects 0.000 claims description 2
- 235000017471 coenzyme Q10 Nutrition 0.000 claims description 2
- 229940110767 coenzyme Q10 Drugs 0.000 claims description 2
- ACTIUHUUMQJHFO-UPTCCGCDSA-N coenzyme Q10 Chemical compound COC1=C(OC)C(=O)C(C\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CC\C=C(/C)CCC=C(C)C)=C(C)C1=O ACTIUHUUMQJHFO-UPTCCGCDSA-N 0.000 claims description 2
- 229960003624 creatine Drugs 0.000 claims description 2
- 239000006046 creatine Substances 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 201000009339 glycogen storage disease VII Diseases 0.000 claims description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 2
- 201000006913 intermediate spinal muscular atrophy Diseases 0.000 claims description 2
- 239000011707 mineral Substances 0.000 claims description 2
- 239000003900 neurotrophic factor Substances 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 239000003881 protein kinase C inhibitor Substances 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 210000005239 tubule Anatomy 0.000 claims description 2
- 208000032471 type 1 spinal muscular atrophy Diseases 0.000 claims description 2
- 208000032521 type II spinal muscular atrophy Diseases 0.000 claims description 2
- 208000032527 type III spinal muscular atrophy Diseases 0.000 claims description 2
- 208000005606 type IV spinal muscular atrophy Diseases 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 208000029402 Bulbospinal muscular atrophy Diseases 0.000 claims 2
- 208000034965 Nemaline Myopathies Diseases 0.000 claims 2
- 238000011260 co-administration Methods 0.000 claims 2
- 108700016228 AMP deaminases Proteins 0.000 claims 1
- 108700043208 Dimauro disease Proteins 0.000 claims 1
- 208000036119 Frailty Diseases 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 206010003549 asthenia Diseases 0.000 claims 1
- 125000003473 lipid group Chemical group 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 201000008752 progressive muscular atrophy Diseases 0.000 claims 1
- 201000000980 schizophrenia Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 230000002103 transcriptional effect Effects 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 15
- -1 Nodal Proteins 0.000 abstract description 5
- 235000018102 proteins Nutrition 0.000 description 79
- 102000007350 Bone Morphogenetic Proteins Human genes 0.000 description 45
- 108010007726 Bone Morphogenetic Proteins Proteins 0.000 description 45
- 229940112869 bone morphogenetic protein Drugs 0.000 description 43
- 230000000694 effects Effects 0.000 description 26
- 241000699666 Mus <mouse, genus> Species 0.000 description 23
- 238000009396 hybridization Methods 0.000 description 22
- 208000022621 Caronte Diseases 0.000 description 21
- 150000007523 nucleic acids Chemical class 0.000 description 20
- 102000039446 nucleic acids Human genes 0.000 description 18
- 108020004707 nucleic acids Proteins 0.000 description 18
- 208000024891 symptom Diseases 0.000 description 18
- 235000001014 amino acid Nutrition 0.000 description 17
- 230000006870 function Effects 0.000 description 17
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 16
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 16
- 210000005036 nerve Anatomy 0.000 description 15
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 13
- 108091034117 Oligonucleotide Proteins 0.000 description 13
- 102000045246 noggin Human genes 0.000 description 13
- 108700007229 noggin Proteins 0.000 description 13
- 208000033808 peripheral neuropathy Diseases 0.000 description 13
- 239000008194 pharmaceutical composition Substances 0.000 description 13
- 208000014674 injury Diseases 0.000 description 12
- 241000894007 species Species 0.000 description 12
- 206010033128 Ovarian cancer Diseases 0.000 description 11
- 206010061535 Ovarian neoplasm Diseases 0.000 description 11
- 206010049811 Extraskeletal ossification Diseases 0.000 description 10
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 10
- 208000034970 Heterotopic Ossification Diseases 0.000 description 10
- 238000002560 therapeutic procedure Methods 0.000 description 10
- 208000024827 Alzheimer disease Diseases 0.000 description 9
- 208000018737 Parkinson disease Diseases 0.000 description 9
- 210000003169 central nervous system Anatomy 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 210000000578 peripheral nerve Anatomy 0.000 description 9
- 208000023275 Autoimmune disease Diseases 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 8
- 201000011510 cancer Diseases 0.000 description 8
- 230000003472 neutralizing effect Effects 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 7
- 101000762379 Homo sapiens Bone morphogenetic protein 4 Proteins 0.000 description 7
- 208000027418 Wounds and injury Diseases 0.000 description 7
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 7
- 230000004069 differentiation Effects 0.000 description 7
- 229940011871 estrogen Drugs 0.000 description 7
- 239000000262 estrogen Substances 0.000 description 7
- 230000001404 mediated effect Effects 0.000 description 7
- 230000004770 neurodegeneration Effects 0.000 description 7
- 210000002569 neuron Anatomy 0.000 description 7
- 201000008482 osteoarthritis Diseases 0.000 description 7
- 229940124597 therapeutic agent Drugs 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 108010069091 Dystrophin Proteins 0.000 description 6
- 101000715732 Mus musculus Cerberus Proteins 0.000 description 6
- 206010036105 Polyneuropathy Diseases 0.000 description 6
- 241000269370 Xenopus <genus> Species 0.000 description 6
- 125000003275 alpha amino acid group Chemical group 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 206010012601 diabetes mellitus Diseases 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000003018 immunoassay Methods 0.000 description 6
- 238000010369 molecular cloning Methods 0.000 description 6
- 230000035772 mutation Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000002027 skeletal muscle Anatomy 0.000 description 6
- 210000000130 stem cell Anatomy 0.000 description 6
- 201000001320 Atherosclerosis Diseases 0.000 description 5
- 108050006583 Growth/differentiation factor 8 Proteins 0.000 description 5
- 208000023105 Huntington disease Diseases 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 239000000556 agonist Substances 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 5
- 210000004958 brain cell Anatomy 0.000 description 5
- 230000009260 cross reactivity Effects 0.000 description 5
- 230000034994 death Effects 0.000 description 5
- 238000012217 deletion Methods 0.000 description 5
- 230000037430 deletion Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 210000001428 peripheral nervous system Anatomy 0.000 description 5
- 230000007824 polyneuropathy Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 230000008733 trauma Effects 0.000 description 5
- 208000016261 weight loss Diseases 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 4
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 4
- 241000287828 Gallus gallus Species 0.000 description 4
- 101000869690 Homo sapiens Protein S100-A8 Proteins 0.000 description 4
- 206010024229 Leprosy Diseases 0.000 description 4
- 208000010428 Muscle Weakness Diseases 0.000 description 4
- 206010028372 Muscular weakness Diseases 0.000 description 4
- 206010029240 Neuritis Diseases 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 208000008558 Osteophyte Diseases 0.000 description 4
- 241001494479 Pecora Species 0.000 description 4
- 102100032442 Protein S100-A8 Human genes 0.000 description 4
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 4
- 210000001130 astrocyte Anatomy 0.000 description 4
- 230000000903 blocking effect Effects 0.000 description 4
- 210000004899 c-terminal region Anatomy 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000000875 corresponding effect Effects 0.000 description 4
- 210000004714 cranial suture Anatomy 0.000 description 4
- 210000003414 extremity Anatomy 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 238000002844 melting Methods 0.000 description 4
- 230000008018 melting Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 230000007170 pathology Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 230000000750 progressive effect Effects 0.000 description 4
- 230000035755 proliferation Effects 0.000 description 4
- 230000001953 sensory effect Effects 0.000 description 4
- 210000003625 skull Anatomy 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010012289 Dementia Diseases 0.000 description 3
- 102000001039 Dystrophin Human genes 0.000 description 3
- 241000283086 Equidae Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 102100030590 Mothers against decapentaplegic homolog 6 Human genes 0.000 description 3
- 101710143114 Mothers against decapentaplegic homolog 6 Proteins 0.000 description 3
- 102100030608 Mothers against decapentaplegic homolog 7 Human genes 0.000 description 3
- 206010028289 Muscle atrophy Diseases 0.000 description 3
- 208000028389 Nerve injury Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 206010035664 Pneumonia Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 101700026522 SMAD7 Proteins 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 102000013814 Wnt Human genes 0.000 description 3
- 108050003627 Wnt Proteins 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 210000001188 articular cartilage Anatomy 0.000 description 3
- 238000003556 assay Methods 0.000 description 3
- 230000036523 atherogenesis Effects 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- 238000002648 combination therapy Methods 0.000 description 3
- 235000018417 cysteine Nutrition 0.000 description 3
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 3
- 230000007850 degeneration Effects 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 102000015694 estrogen receptors Human genes 0.000 description 3
- 108010038795 estrogen receptors Proteins 0.000 description 3
- 201000010934 exostosis Diseases 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- 150000002632 lipids Chemical group 0.000 description 3
- 230000033001 locomotion Effects 0.000 description 3
- 238000012423 maintenance Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 201000005518 mononeuropathy Diseases 0.000 description 3
- 210000002161 motor neuron Anatomy 0.000 description 3
- 108700029849 mouse Dte Proteins 0.000 description 3
- 230000020763 muscle atrophy Effects 0.000 description 3
- 230000008764 nerve damage Effects 0.000 description 3
- 201000001119 neuropathy Diseases 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002864 sequence alignment Methods 0.000 description 3
- 230000009870 specific binding Effects 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 201000004595 synovitis Diseases 0.000 description 3
- 210000002435 tendon Anatomy 0.000 description 3
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 2
- HVCOBJNICQPDBP-UHFFFAOYSA-N 3-[3-[3,5-dihydroxy-6-methyl-4-(3,4,5-trihydroxy-6-methyloxan-2-yl)oxyoxan-2-yl]oxydecanoyloxy]decanoic acid;hydrate Chemical compound O.OC1C(OC(CC(=O)OC(CCCCCCC)CC(O)=O)CCCCCCC)OC(C)C(O)C1OC1C(O)C(O)C(O)C(C)O1 HVCOBJNICQPDBP-UHFFFAOYSA-N 0.000 description 2
- 208000002016 Adenosine monophosphate deaminase deficiency Diseases 0.000 description 2
- 208000000044 Amnesia Diseases 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 2
- 201000004569 Blindness Diseases 0.000 description 2
- 208000010392 Bone Fractures Diseases 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- 206010007710 Cartilage injury Diseases 0.000 description 2
- 241000252212 Danio rerio Species 0.000 description 2
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 206010017076 Fracture Diseases 0.000 description 2
- 208000024412 Friedreich ataxia Diseases 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102100038367 Gremlin-1 Human genes 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 208000028782 Hereditary disease Diseases 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 2
- 208000026350 Inborn Genetic disease Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 208000026139 Memory disease Diseases 0.000 description 2
- 208000024556 Mendelian disease Diseases 0.000 description 2
- 208000034819 Mobility Limitation Diseases 0.000 description 2
- 102100025751 Mothers against decapentaplegic homolog 2 Human genes 0.000 description 2
- 101710143123 Mothers against decapentaplegic homolog 2 Proteins 0.000 description 2
- 102100025748 Mothers against decapentaplegic homolog 3 Human genes 0.000 description 2
- 101710143111 Mothers against decapentaplegic homolog 3 Proteins 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 206010034719 Personality change Diseases 0.000 description 2
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102000007453 TGF-beta Superfamily Proteins Human genes 0.000 description 2
- 108010085004 TGF-beta Superfamily Proteins Proteins 0.000 description 2
- 108010009583 Transforming Growth Factors Proteins 0.000 description 2
- 102000009618 Transforming Growth Factors Human genes 0.000 description 2
- 206010044565 Tremor Diseases 0.000 description 2
- 210000001766 X chromosome Anatomy 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 210000001367 artery Anatomy 0.000 description 2
- 230000037444 atrophy Effects 0.000 description 2
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 2
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 210000002805 bone matrix Anatomy 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- RZEKVGVHFLEQIL-UHFFFAOYSA-N celecoxib Chemical compound C1=CC(C)=CC=C1C1=CC(C(F)(F)F)=NN1C1=CC=C(S(N)(=O)=O)C=C1 RZEKVGVHFLEQIL-UHFFFAOYSA-N 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 230000009137 competitive binding Effects 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008878 coupling Effects 0.000 description 2
- 238000010168 coupling process Methods 0.000 description 2
- 238000005859 coupling reaction Methods 0.000 description 2
- 210000003792 cranial nerve Anatomy 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000010494 dissociation reaction Methods 0.000 description 2
- 230000005593 dissociations Effects 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000003828 downregulation Effects 0.000 description 2
- 230000004064 dysfunction Effects 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 208000037957 feline spongiform encephalopathy Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 208000016361 genetic disease Diseases 0.000 description 2
- 230000013632 homeostatic process Effects 0.000 description 2
- 102000049307 human ACVR1B Human genes 0.000 description 2
- 102000055895 human ACVR1C Human genes 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000002757 inflammatory effect Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000003780 insertion Methods 0.000 description 2
- 230000037431 insertion Effects 0.000 description 2
- 238000001361 intraarterial administration Methods 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 208000028867 ischemia Diseases 0.000 description 2
- 210000003041 ligament Anatomy 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 102000006240 membrane receptors Human genes 0.000 description 2
- 108020004084 membrane receptors Proteins 0.000 description 2
- 230000006984 memory degeneration Effects 0.000 description 2
- 208000023060 memory loss Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 210000004165 myocardium Anatomy 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 208000015122 neurodegenerative disease Diseases 0.000 description 2
- 210000004498 neuroglial cell Anatomy 0.000 description 2
- 230000007823 neuropathy Effects 0.000 description 2
- 238000007899 nucleic acid hybridization Methods 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 208000027232 peripheral nervous system disease Diseases 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000003019 respiratory muscle Anatomy 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 210000004116 schwann cell Anatomy 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000004096 skeletal muscle tissue growth Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 229960001603 tamoxifen Drugs 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- DODQJNMQWMSYGS-QPLCGJKRSA-N 4-[(z)-1-[4-[2-(dimethylamino)ethoxy]phenyl]-1-phenylbut-1-en-2-yl]phenol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 DODQJNMQWMSYGS-QPLCGJKRSA-N 0.000 description 1
- 206010000117 Abnormal behaviour Diseases 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 108010059616 Activins Proteins 0.000 description 1
- 208000007848 Alcoholism Diseases 0.000 description 1
- OGSPWJRAVKPPFI-UHFFFAOYSA-N Alendronic Acid Chemical compound NCCCC(O)(P(O)(O)=O)P(O)(O)=O OGSPWJRAVKPPFI-UHFFFAOYSA-N 0.000 description 1
- 208000003808 Amyloid Neuropathies Diseases 0.000 description 1
- 208000000103 Anorexia Nervosa Diseases 0.000 description 1
- 108010032595 Antibody Binding Sites Proteins 0.000 description 1
- 206010061666 Autonomic neuropathy Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 208000012639 Balance disease Diseases 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 206010004954 Birth trauma Diseases 0.000 description 1
- 108010049931 Bone Morphogenetic Protein 2 Proteins 0.000 description 1
- 108010049870 Bone Morphogenetic Protein 7 Proteins 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- 102100024506 Bone morphogenetic protein 2 Human genes 0.000 description 1
- 102100022544 Bone morphogenetic protein 7 Human genes 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- OBMZMSLWNNWEJA-XNCRXQDQSA-N C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 Chemical compound C1=CC=2C(C[C@@H]3NC(=O)[C@@H](NC(=O)[C@H](NC(=O)N(CC#CCN(CCCC[C@H](NC(=O)[C@@H](CC4=CC=CC=C4)NC3=O)C(=O)N)CC=C)NC(=O)[C@@H](N)C)CC3=CNC4=C3C=CC=C4)C)=CNC=2C=C1 OBMZMSLWNNWEJA-XNCRXQDQSA-N 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 102000007345 Chromogranins Human genes 0.000 description 1
- 108010007718 Chromogranins Proteins 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 206010062346 Congenital neuropathy Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 208000019736 Cranial nerve disease Diseases 0.000 description 1
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 description 1
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 description 1
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 description 1
- 206010011469 Crying Diseases 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 208000030814 Eating disease Diseases 0.000 description 1
- DBVJJBKOTRCVKF-UHFFFAOYSA-N Etidronic acid Chemical compound OP(=O)(O)C(O)(C)P(O)(O)=O DBVJJBKOTRCVKF-UHFFFAOYSA-N 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108091008794 FGF receptors Proteins 0.000 description 1
- 208000019454 Feeding and Eating disease Diseases 0.000 description 1
- 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
- 102000003974 Fibroblast growth factor 2 Human genes 0.000 description 1
- 108090000379 Fibroblast growth factor 2 Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102100038353 Gremlin-2 Human genes 0.000 description 1
- 108010051696 Growth Hormone Proteins 0.000 description 1
- 206010056438 Growth hormone deficiency Diseases 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 208000035895 Guillain-Barré syndrome Diseases 0.000 description 1
- 102100030634 Homeobox protein OTX2 Human genes 0.000 description 1
- 101000893545 Homo sapiens Growth/differentiation factor 11 Proteins 0.000 description 1
- 101000886562 Homo sapiens Growth/differentiation factor 8 Proteins 0.000 description 1
- 101000584400 Homo sapiens Homeobox protein OTX2 Proteins 0.000 description 1
- 102000003839 Human Proteins Human genes 0.000 description 1
- 108090000144 Human Proteins Proteins 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- MPBVHIBUJCELCL-UHFFFAOYSA-N Ibandronate Chemical compound CCCCCN(C)CCC(O)(P(O)(O)=O)P(O)(O)=O MPBVHIBUJCELCL-UHFFFAOYSA-N 0.000 description 1
- JJKOTMDDZAJTGQ-DQSJHHFOSA-N Idoxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN2CCCC2)=CC=1)/C1=CC=C(I)C=C1 JJKOTMDDZAJTGQ-DQSJHHFOSA-N 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 206010022031 Inherited neuropathies Diseases 0.000 description 1
- 102100026818 Inhibin beta E chain Human genes 0.000 description 1
- 102000002746 Inhibins Human genes 0.000 description 1
- 108010004250 Inhibins Proteins 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 206010049567 Miller Fisher syndrome Diseases 0.000 description 1
- 206010027910 Mononeuritis Diseases 0.000 description 1
- 206010027951 Mood swings Diseases 0.000 description 1
- 102100025744 Mothers against decapentaplegic homolog 1 Human genes 0.000 description 1
- 206010061296 Motor dysfunction Diseases 0.000 description 1
- 108090000143 Mouse Proteins Proteins 0.000 description 1
- 101001032860 Mus musculus Gremlin-2 Proteins 0.000 description 1
- 101000996033 Mus musculus Nodal Proteins 0.000 description 1
- 206010028311 Muscle hypertrophy Diseases 0.000 description 1
- 206010052904 Musculoskeletal stiffness Diseases 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 102000006386 Myelin Proteins Human genes 0.000 description 1
- 108010083674 Myelin Proteins Proteins 0.000 description 1
- 201000004404 Neurofibroma Diseases 0.000 description 1
- 108700024442 Nodal Proteins 0.000 description 1
- 102000044547 Nodal Human genes 0.000 description 1
- 208000014723 Oculomotor Nerve disease Diseases 0.000 description 1
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 208000007542 Paresis Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 101710176384 Peptide 1 Proteins 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 108091000080 Phosphotransferase Proteins 0.000 description 1
- 208000005374 Poisoning Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 108700008625 Reporter Genes Proteins 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- FTALBRSUTCGOEG-UHFFFAOYSA-N Riluzole Chemical compound C1=C(OC(F)(F)F)C=C2SC(N)=NC2=C1 FTALBRSUTCGOEG-UHFFFAOYSA-N 0.000 description 1
- IIDJRNMFWXDHID-UHFFFAOYSA-N Risedronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CC1=CC=CN=C1 IIDJRNMFWXDHID-UHFFFAOYSA-N 0.000 description 1
- 101700032040 SMAD1 Proteins 0.000 description 1
- 208000021811 Sandhoff disease Diseases 0.000 description 1
- 102100034201 Sclerostin Human genes 0.000 description 1
- 108050006698 Sclerostin Proteins 0.000 description 1
- 102100022432 Sclerostin domain-containing protein 1 Human genes 0.000 description 1
- 101710169324 Sclerostin domain-containing protein 1 Proteins 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 206010040021 Sensory abnormalities Diseases 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 208000020221 Short stature Diseases 0.000 description 1
- 102100038803 Somatotropin Human genes 0.000 description 1
- 102000043168 TGF-beta family Human genes 0.000 description 1
- 108091085018 TGF-beta family Proteins 0.000 description 1
- 241001441722 Takifugu rubripes Species 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- DKJJVAGXPKPDRL-UHFFFAOYSA-N Tiludronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)SC1=CC=C(Cl)C=C1 DKJJVAGXPKPDRL-UHFFFAOYSA-N 0.000 description 1
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 1
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 1
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 208000005181 Varicella Zoster Virus Infection Diseases 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 101000996032 Xenopus laevis Nodal homolog Proteins 0.000 description 1
- 241000269457 Xenopus tropicalis Species 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000488 activin Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229940062527 alendronate Drugs 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940126575 aminoglycoside Drugs 0.000 description 1
- 230000019552 anatomical structure morphogenesis Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 210000000467 autonomic pathway Anatomy 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000003376 axonal effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 238000005452 bending Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 102000023732 binding proteins Human genes 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000002306 biochemical method Methods 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 229960000074 biopharmaceutical Drugs 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000018678 bone mineralization Effects 0.000 description 1
- 230000008416 bone turnover Effects 0.000 description 1
- 201000006431 brachial plexus neuropathy Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000001925 catabolic effect Effects 0.000 description 1
- 229940047495 celebrex Drugs 0.000 description 1
- 229960000590 celecoxib Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 210000001612 chondrocyte Anatomy 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Substances OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 1
- ACSIXWWBWUQEHA-UHFFFAOYSA-N clodronic acid Chemical compound OP(O)(=O)C(Cl)(Cl)P(O)(O)=O ACSIXWWBWUQEHA-UHFFFAOYSA-N 0.000 description 1
- 229960002286 clodronic acid Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 208000018631 connective tissue disease Diseases 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 229940111134 coxibs Drugs 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N cystine group Chemical group C([C@@H](C(=O)O)N)SSC[C@@H](C(=O)O)N LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 230000003210 demyelinating effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- JFGHPLSPUGOSLV-UHFFFAOYSA-L disodium;[3-(dimethylamino)-1-hydroxy-1-[hydroxy(oxido)phosphoryl]propyl]-hydroxyphosphinate Chemical compound [Na+].[Na+].CN(C)CCC(O)(P(O)(O)=O)P([O-])([O-])=O JFGHPLSPUGOSLV-UHFFFAOYSA-L 0.000 description 1
- 235000014632 disordered eating Nutrition 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 230000007783 downstream signaling Effects 0.000 description 1
- 229950004203 droloxifene Drugs 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940073514 dynacin Drugs 0.000 description 1
- 235000005686 eating Nutrition 0.000 description 1
- 230000013020 embryo development Effects 0.000 description 1
- 210000004212 embryonic organizer Anatomy 0.000 description 1
- 230000004970 emotional disturbance Effects 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- 229940009626 etidronate Drugs 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 230000007045 gastrulation Effects 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000023266 generation of precursor metabolites and energy Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N glycerol 1-phosphate Chemical compound OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 210000004565 granule cell Anatomy 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 231100000001 growth retardation Toxicity 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000016354 hearing loss disease Diseases 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000011577 humanized mouse model Methods 0.000 description 1
- 230000008348 humoral response Effects 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 229940015872 ibandronate Drugs 0.000 description 1
- 229950002248 idoxifene Drugs 0.000 description 1
- 210000001822 immobilized cell Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- LWRDQHOZTAOILO-UHFFFAOYSA-N incadronic acid Chemical compound OP(O)(=O)C(P(O)(O)=O)NC1CCCCCC1 LWRDQHOZTAOILO-UHFFFAOYSA-N 0.000 description 1
- 229950006971 incadronic acid Drugs 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000000893 inhibin Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 230000032631 intramembranous ossification Effects 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 210000003292 kidney cell Anatomy 0.000 description 1
- 238000011813 knockout mouse model Methods 0.000 description 1
- 108020001756 ligand binding domains Proteins 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 1
- 210000005265 lung cell Anatomy 0.000 description 1
- 230000002132 lysosomal effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000001071 malnutrition Effects 0.000 description 1
- 235000000824 malnutrition Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000003716 mesoderm Anatomy 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 208000013734 mononeuritis simplex Diseases 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000012042 muscle hypertrophy Effects 0.000 description 1
- 210000005012 myelin Anatomy 0.000 description 1
- 210000003007 myelin sheath Anatomy 0.000 description 1
- 208000019382 nerve compression syndrome Diseases 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000004296 neuralgia Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 230000000955 neuroendocrine Effects 0.000 description 1
- 230000004751 neurological system process Effects 0.000 description 1
- 230000000508 neurotrophic effect Effects 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 235000006286 nutrient intake Nutrition 0.000 description 1
- 208000015380 nutritional deficiency disease Diseases 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000002751 oligonucleotide probe Substances 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000000399 orthopedic effect Effects 0.000 description 1
- 230000003534 oscillatory effect Effects 0.000 description 1
- 210000000963 osteoblast Anatomy 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N pamidronate Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 238000000059 patterning Methods 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 102000020233 phosphotransferase Human genes 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 208000019629 polyneuritis Diseases 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 235000013594 poultry meat Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000012514 protein characterization Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 230000009430 psychological distress Effects 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- GZUITABIAKMVPG-UHFFFAOYSA-N raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 1
- 229960004622 raloxifene Drugs 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 235000002137 reduced nutrient intake Nutrition 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000007261 regionalization Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 229960004181 riluzole Drugs 0.000 description 1
- 229940089617 risedronate Drugs 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 208000008864 scrapie Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 230000037152 sensory function Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000012488 skeletal system development Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 210000002023 somite Anatomy 0.000 description 1
- 208000020431 spinal cord injury Diseases 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000012916 structural analysis Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 210000003448 thoracic nerve Anatomy 0.000 description 1
- 229940019375 tiludronate Drugs 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 229960004394 topiramate Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 210000001364 upper extremity Anatomy 0.000 description 1
- 208000010531 varicella zoster infection Diseases 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- WJJYZXPHLSLMGE-UHFFFAOYSA-N xaliproden Chemical compound FC(F)(F)C1=CC=CC(C=2CCN(CCC=3C=C4C=CC=CC4=CC=3)CC=2)=C1 WJJYZXPHLSLMGE-UHFFFAOYSA-N 0.000 description 1
- 229960004664 xaliproden Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Diabetes (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Cardiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US57506204P | 2004-05-27 | 2004-05-27 | |
| PCT/US2005/018928 WO2005115439A2 (en) | 2004-05-27 | 2005-05-27 | Cerberus/coco derivatives and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2008500373A true JP2008500373A (ja) | 2008-01-10 |
| JP2008500373A5 JP2008500373A5 (enExample) | 2008-07-17 |
Family
ID=35451405
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007515450A Pending JP2008500373A (ja) | 2004-05-27 | 2005-05-27 | ケルベロス（Ｃｅｒｂｅｒｕｓ）／ココ（Ｃｏｃｏ）誘導体およびそれらの使用 |
Country Status (8)
| Country | Link |
|---|---|
| US (4) | US20100183695A1 (enExample) |
| EP (1) | EP1755648A2 (enExample) |
| JP (1) | JP2008500373A (enExample) |
| KR (1) | KR20070026650A (enExample) |
| AU (1) | AU2005247508A1 (enExample) |
| CA (1) | CA2567810A1 (enExample) |
| IL (1) | IL179602A0 (enExample) |
| WO (1) | WO2005115439A2 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9045553B2 (en) * | 2004-05-27 | 2015-06-02 | Acceleron Pharma, Inc. | Cerberus/Coco derivatives and uses thereof |
| WO2007123391A1 (en) | 2006-04-20 | 2007-11-01 | Academisch Ziekenhuis Leiden | Therapeutic intervention in a genetic disease in an individual by modifying expression of an aberrantly expressed gene. |
| WO2008018795A1 (en) | 2006-08-11 | 2008-02-14 | Prosensa Technologies B.V. | Methods and means for treating dna repeat instability associated genetic disorders |
| WO2008073351A2 (en) * | 2006-12-08 | 2008-06-19 | Acceleron Pharma Inc. | Uses of cerberus, coco and derivatives thereof |
| CA3039330C (en) * | 2007-02-09 | 2021-11-09 | Acceleron Pharma Inc. | Activin-actriia antagonists and uses for promoting bone growth in cancer patients |
| US20100233137A1 (en) * | 2007-02-27 | 2010-09-16 | Lanx, Inc. | Compositions and Methods for Modification of Target Cells and to Their Uses Thereof |
| WO2008151119A2 (en) * | 2007-06-01 | 2008-12-11 | Lanx, Llc | Compositions and methods for use of scar tissue in repair of weight bearing surfaces |
| USRE48468E1 (en) | 2007-10-26 | 2021-03-16 | Biomarin Technologies B.V. | Means and methods for counteracting muscle disorders |
| PT2203173E (pt) | 2007-10-26 | 2016-03-15 | Academisch Ziekenhuis Leiden | Resumo |
| WO2009105606A1 (en) * | 2008-02-21 | 2009-08-27 | Lanx, Llc | Compositions and methods for use of scar tissue in repair of weight bearing surfaces |
| EP2119783A1 (en) | 2008-05-14 | 2009-11-18 | Prosensa Technologies B.V. | Method for efficient exon (44) skipping in Duchenne Muscular Dystrophy and associated means |
| US9149319B2 (en) * | 2008-09-23 | 2015-10-06 | Lanx, Llc | Methods and compositions for stabilization of a vertebra |
| NZ595955A (en) | 2009-04-24 | 2012-10-26 | Prosensa Technologies Bv | Oligonucleotide comprising an inosine for treating dmd |
| CN102482339B (zh) | 2009-06-08 | 2015-06-17 | 阿塞勒隆制药公司 | 用于增加产热脂肪细胞的方法 |
| WO2010148010A1 (en) * | 2009-06-15 | 2010-12-23 | 4S3 Bioscience Inc. | Methods and compositions for treatment of myotubular myopathy using chimeric polypeptides comprising myotubularih 1 (mtm1) polypeptides |
| CA2779472C (en) | 2009-11-03 | 2021-03-16 | Acceleron Pharma Inc. | The use of a composition comprising an activin type iib receptor polypeptide in the treatment of fatty liver disease |
| DE102010052941A1 (de) * | 2010-11-18 | 2012-05-24 | Eberhard-Karls-Universität Tübingen Universitätsklinikum | Therapeutisches Protein |
| NZ627896A (en) | 2012-01-27 | 2016-11-25 | Biomarin Technologies B V | Rna modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy |
| CA2911514A1 (en) | 2013-05-06 | 2014-11-13 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| EP3741375A1 (en) * | 2014-07-17 | 2020-11-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for treating neuromuscular junction-related diseases |
| JP6706617B2 (ja) | 2014-11-06 | 2020-06-10 | スカラー ロック インコーポレイテッドＳｃｈｏｌａｒ Ｒｏｃｋ，Ｉｎｃ． | 抗プロ／潜在型−ミオスタチン抗体およびその使用 |
| RS62330B1 (sr) | 2015-09-15 | 2021-10-29 | Scholar Rock Inc | Antitela pro/latentnog miostatina i njihova upotreba |
| US10287345B2 (en) | 2016-01-08 | 2019-05-14 | Scholar Rock, Inc. | Methods for inhibiting myostatin activation by administering anti-pro/latent myostatin antibodies |
| EP3439741A4 (en) | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
| KR20210082548A (ko) | 2016-06-13 | 2021-07-05 | 스칼러 락, 인크. | 미오스타틴 억제제의 용도 및 조합 요법 |
| SI3565592T1 (sl) | 2017-01-06 | 2023-05-31 | Scholar Rock, Inc. | Zdravljenje presnovnih bolezni z zaviranjem aktivacije miostatina |
| CN109758616B (zh) * | 2019-03-05 | 2021-11-19 | 中国医学科学院北京协和医院 | 一种新型促进骨再生材料及其制备方法 |
| KR20250122524A (ko) | 2022-12-22 | 2025-08-13 | 스칼러 락, 인크. | 미오스타틴 활성화의 선택적이고 강력한 억제 항체 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526535A (ja) * | 1997-04-29 | 2001-12-18 | リジェネロン ファーマシューティカルズ，インコーポレイテッド | ヒトケルベロスタンパク質 |
| WO2003072714A2 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6133232A (en) * | 1996-06-20 | 2000-10-17 | The Regents Of The University Of California | Endoderm, cardiac and neural inducing factors |
| WO1998034951A1 (en) | 1997-02-11 | 1998-08-13 | Amrad Operations Pty. Ltd. | A new cytokine family and uses thereof |
| US5935852A (en) | 1997-07-03 | 1999-08-10 | Genetics Institute, Inc. | DNA molecules encoding mammalian cerberus-like proteins |
| US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
| CA2319703C (en) | 1998-02-05 | 2005-09-20 | The Johns Hopkins University School Of Medicine | Growth differentiation factor-8 |
| US20040009535A1 (en) | 1998-11-27 | 2004-01-15 | Celltech R&D, Inc. | Compositions and methods for increasing bone mineralization |
| WO2000055193A2 (en) | 1999-03-12 | 2000-09-21 | Regeneron Pharmaceuticals, Inc. | Human dan/cerberus related protein 6 (dcr6) |
| WO2002032929A2 (en) | 2000-10-19 | 2002-04-25 | Genaissance Pharmaceuticals, Inc. | Haplotypes of the cer1 gene |
| AU2002243495A1 (en) | 2001-01-12 | 2002-07-24 | University Of Medicine And Dentistry Of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| EP1383867A2 (en) | 2001-03-23 | 2004-01-28 | Axordia Limited | Stem cell differentiation |
| WO2002078516A2 (en) | 2001-03-30 | 2002-10-10 | Corixa Corporation | Compositions and methods for the therapy and diagnosis of cancer |
| GB0111004D0 (en) | 2001-05-04 | 2001-06-27 | Univ Sheffield | Screening method |
| US6513196B2 (en) | 2001-06-22 | 2003-02-04 | Maytag Corporation | Top cover hinge and method for using same |
| CN1161875C (zh) | 2001-07-01 | 2004-08-11 | 周符明 | 开关稳功率电源 |
| GB0118223D0 (en) | 2001-07-26 | 2001-09-19 | Univ Sheffield | Stem loop RNA |
| CN1685055A (zh) | 2001-10-31 | 2005-10-19 | 爱尔康公司 | 骨形态发生蛋白(bmp)、bmp受体和bmp结合蛋白及它们在诊断和治疗青光眼中的用途 |
| GB0130738D0 (en) | 2001-12-21 | 2002-02-06 | Serono Internat S A | Protein |
| US20030134790A1 (en) | 2002-01-11 | 2003-07-17 | University Of Medicine And Dentistry Of New Jersey | Bone Morphogenetic Protein-2 And Bone Morphogenetic Protein-4 In The Treatment And Diagnosis Of Cancer |
| US7193069B2 (en) | 2002-03-22 | 2007-03-20 | Research Association For Biotechnology | Full-length cDNA |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| AU2003276430A1 (en) | 2002-06-14 | 2003-12-31 | Stowers Institute For Medical Research | Wise/sost nucleic acid sequences and amino acid sequences |
| WO2003106654A2 (en) | 2002-06-14 | 2003-12-24 | Diversa Corporation | Xylanases, nucleic adics encoding them and methods for making and using them |
| EP2272864A3 (en) * | 2002-12-20 | 2011-02-16 | Amgen Inc. | Binding agents which inhibit myostatin |
| WO2004074460A2 (en) | 2003-02-19 | 2004-09-02 | The Rockefeller University | Nucleotide and protein sequences of coc genes and methods based thereon |
-
2005
- 2005-05-27 WO PCT/US2005/018928 patent/WO2005115439A2/en not_active Ceased
- 2005-05-27 KR KR1020067027257A patent/KR20070026650A/ko not_active Withdrawn
- 2005-05-27 AU AU2005247508A patent/AU2005247508A1/en not_active Abandoned
- 2005-05-27 US US11/597,182 patent/US20100183695A1/en not_active Abandoned
- 2005-05-27 CA CA002567810A patent/CA2567810A1/en not_active Abandoned
- 2005-05-27 EP EP05780089A patent/EP1755648A2/en not_active Withdrawn
- 2005-05-27 JP JP2007515450A patent/JP2008500373A/ja active Pending
- 2005-05-27 US US11/140,024 patent/US7316998B2/en not_active Expired - Lifetime
-
2006
- 2006-11-27 IL IL179602A patent/IL179602A0/en unknown
-
2007
- 2007-08-20 US US11/894,289 patent/US7981857B2/en active Active
-
2012
- 2012-06-26 US US13/533,733 patent/US20130029908A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2001526535A (ja) * | 1997-04-29 | 2001-12-18 | リジェネロン ファーマシューティカルズ，インコーポレイテッド | ヒトケルベロスタンパク質 |
| WO2003072714A2 (en) * | 2002-02-21 | 2003-09-04 | Wyeth | Follistatin domain containing proteins |
Also Published As
| Publication number | Publication date |
|---|---|
| US20130029908A1 (en) | 2013-01-31 |
| KR20070026650A (ko) | 2007-03-08 |
| CA2567810A1 (en) | 2005-12-08 |
| US20060025340A1 (en) | 2006-02-02 |
| WO2005115439A9 (en) | 2006-02-02 |
| IL179602A0 (en) | 2007-05-15 |
| US7981857B2 (en) | 2011-07-19 |
| AU2005247508A1 (en) | 2005-12-08 |
| WO2005115439A2 (en) | 2005-12-08 |
| US20090192080A1 (en) | 2009-07-30 |
| EP1755648A2 (en) | 2007-02-28 |
| US20100183695A1 (en) | 2010-07-22 |
| WO2005115439A3 (en) | 2007-09-13 |
| US7316998B2 (en) | 2008-01-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7981857B2 (en) | Cerberus/coco derivatives and uses thereof | |
| US9255137B2 (en) | Methods of promoting fat loss comprising administering an ALK7 inhibitor | |
| US20050260616A1 (en) | Nucleotide and protein sequences of Nogo genes and methods based thereon | |
| US8796199B2 (en) | Uses of Cerberus and derivatives thereof | |
| US7585671B2 (en) | Hedgehog interacting proteins and uses related thereto | |
| US9045553B2 (en) | Cerberus/Coco derivatives and uses thereof | |
| HK1140493A (en) | Nucleotide and protein sequences of nogo genes and methods based thereon |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20080527 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20080527 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110829 |